Помощь пациенту с острой болью в спине – проблемы эффективности и безопасности лечения

1. Крылов В.В., Гринь А. А. О грыжах межпозвонковых дисков и методах лечения больных с этой патологией. Cons. Med. 2009; 11 (9): 5–10.
2. Насонов Е.Л. Противовоспалительная терапия ревматических болезней. М.: М-Сити, 1996.
3. Никифоров А.С., Коновалов А.Н., Гусев Е.И. Клиническая неврология. В 3 т. М.: Медицина, 2002.
4. Acute low back pain: a new paradigm for management. Editorials. BMJ 1996; 313: 1343–4.
5. Caldwell B, Aldington S, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132–40.
6. Carrabba M, Paresce E, Angelini M et al. A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study. Curr Med Res Opin 1995; 13 (6): 343–55.
7. Chou R, Qaseem A, Snow V et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147: 478–91.
8. Colberg K, Hettich M, Sigmund R, Degner F. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Curr Med Res Opin 1996; 13 (7): 363–77.
9. Dreiser R, Le Parc J, Ve?licitat P, Lleu P. Oral meloxicam is effectivе in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac. Inflamm Res 2001; 50 (Suppl. 1): S17–23.
10. Gilbert F, Grant A, Gillan M et al. Scottish Back Trial Group. Low back pain: influence of early MR imaging or CT on treatment and outcome-multicenter randomized trial. Radiology 2004; 231: 343–51.
11. Goei The? H, Lund B, Distel M, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 1997; 5 (4): 283–8.
12. Hagen K, Jamtvedt G, Hilde G, Winnem M. Bed rest bad for back pain, ineffective for sciatica. The updated Cochrane Review of bed rest for low back pain and sciatica. Spine 2005; 30: 542–46.
13. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Rheumatology (Oxford) 1999; 38 (8): 793–945.
14. Helin-Salmivaara A, Saarelainen S, Gro Nroos J et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A casecontrol study in a general population. Scand J Gastroenterol 2007; 42: 923–32.
15. Jellema P, van Tulder M, van Poppel M, Nachemson A. Lumbar supports for prevention and treatment of low back pain: a systematic review within the framework of the Cochrane Back Review Group. Spine 2001; 26: 377–86.
16. Kimura S, Kontani H. Demonstration of Antiallodynic Effects of the Cyclooxygenase-2 Inhibitor Meloxicam on Established Diabetic Neuropathic Pain in Mice. J Pharm Sci 2009; 110 (2): 213–7.
17. Linde?n B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 (Suppl. 1): 35–8.
18. Low Back pain initiavite, WHO, 1999.
19. Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J Rheumatol 1998; 27 (1): 32–37.
20. Luo X, Pietrobon R, Sun S et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004; 29: 79–86.
21. Reginster J, Distel M, Bluhmki E. A double-blind, three-week study to compare the efficacy and safety of meloxicam 7,5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 (Suppl. 1): 17–21.
22. Roumie C, Mitchel E, Kaltenbach L et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39 (7): 2037–45.
23. Royal College of General Practitioners. Clinical Guidelines for the Management of Acute Low Back Pain. London, Royal College of General Practitioners, 1996 and 1999.
24. Ruperto N, Nikishina I, Pachanov E et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: shortand long-term efficacy and safety results. Arthritis Rheum 2005; 52 (2): 563–72.
25. Senna G, Bilo? M, Antonicelli L et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Aller Immunol (Paris) 2004; 36 (6): 215–8.
26. Valat J, Accardo S, Reginster J et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001; 50 (Suppl. 1): S30–34.
27. Van Ryn J, Kink-Eiband M, Kuritsch I et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004; 44 (7): 777–84.
28. van Tulder M. Low back pain (chronic). Clin Evid 2004; 12: 1657–82. Waddell G. The Back Pain Revolution ed. by G. Waddell. 2nd ed. Elsevier Edinburgh 2004; 221–39.
29. van Tulder M, Becker A, Bekkering T et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15 (Suppl. 2): S169–91.
30. Weinstein J, Lurie J, Tosteson T et al. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. N Engl J Med 2007; 356: 2257–70.
31. Wojtulewski J, Schattenkirchner M, Barcelo? P et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 (Suppl. 1): 22–8.
32. Tavakoli M. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. Pharmacoeconomics 2003; 21(6): 443-54.
33. Furst D, Kolba K, Fleischmann R et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29 (3): 436-46.